On November 26-27, the 7th Annual Biomanufacturing Industry Summit was successfully held at the Intercontinental Hefei By IHG. HOLVES showcased its Cla210 series classic laboratory fermenter and K2T-Mini mini tangential flow ultrafiltration（TFF） system. Moving beyond mere product display, the company engaged in cutting-edge industry dialogue, serving as both an enabler and a collaborator. Together with over 800 industry experts and peers, HOLVES witnessed the advancement of biomanufacturing.
 

Unlike traditional exhibitions, this summit's rich academic atmosphere and cutting-edge industry insights provided HOLVES with a novel platform for exchange. At specialized sessions on synthetic biology & enabling technologies, biomanufacturing & cell factories, and thematic events covering biomimetic materials and AI-driven protein engineering, the HOLVES team engaged deeply in discussions, capturing authentic voices from the front lines of R&D.
 

 
“We have heard researchers' urgent demands for product stability, data traceability, and flexibility in small-batch prototyping. This reinforces our conviction that product development must resonate in sync with frontline scientific research and industrialization processes.

—HOLVES Technical Lead Engineer”

 
This frontline feedback has also redefined the value of the Cla210 and K2T-Mini.

 
The Cla210 fermentor is not only a laboratory tool but is becoming an “intelligent laboratory” for synthetic biology research. It provides a stable and reliable cultivation environment for engineered microbial strains and metabolic pathway optimization, supporting the realization of standardized biomanufacturing.
 
At sessions focused on innovative raw materials and biopharmaceuticals, the need for rapid R&D processes with minimal sample loss was frequently highlighted. Many users noted their limited sample quantities often require swift completion of steps like concentration and media exchange. The HOLVES K2T-Mini's low dead volume and high recovery rate significantly reduce sample loss, enabling users to shorten their trial-and-error cycles considerably.
 

With the 15th Five-Year Plan designating biomanufacturing as one of seven future industries, pilot platforms, flagship products, and challenge-based projects are being rolled out across the country. Behind this policy window, the competition remains: “Who can first transform laboratory technology into replicable industrial data?”
 
This experience in Hefei has given HOLVES a profound sense of the rapid growth in the biomanufacturing industry. HOLVES is committed to helping clients achieve breakthroughs from zero to one and scale from one to one hundred at lower costs and in shorter timeframes. Though the summit has concluded, HOLVES looks forward to meeting you again soon!